An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Latest Information Update: 19 Jun 2025
At a glance
- Drugs SHR 7631 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 13 Jun 2025 Status changed from recruiting to completed.
- 06 Aug 2024 Status changed from not yet recruiting to recruiting.
- 14 May 2024 Planned initiation date changed from 1 Apr 2024 to 1 May 2024.